JP7750858B2 - 生産のためのアデノウイルス発現ベクター及び方法並びに細胞株 - Google Patents

生産のためのアデノウイルス発現ベクター及び方法並びに細胞株

Info

Publication number
JP7750858B2
JP7750858B2 JP2022561644A JP2022561644A JP7750858B2 JP 7750858 B2 JP7750858 B2 JP 7750858B2 JP 2022561644 A JP2022561644 A JP 2022561644A JP 2022561644 A JP2022561644 A JP 2022561644A JP 7750858 B2 JP7750858 B2 JP 7750858B2
Authority
JP
Japan
Prior art keywords
vector
seq
adenoviral
sequence
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022561644A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521149A5 (https=
JP2023521149A (ja
Inventor
エクスライン コリン
リョウ ホイチュー
スティーブンズ シーン
Original Assignee
ラング バイオテクノロジー ピービーシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラング バイオテクノロジー ピービーシー filed Critical ラング バイオテクノロジー ピービーシー
Publication of JP2023521149A publication Critical patent/JP2023521149A/ja
Publication of JP2023521149A5 publication Critical patent/JP2023521149A5/ja
Priority to JP2025159003A priority Critical patent/JP2025175172A/ja
Application granted granted Critical
Publication of JP7750858B2 publication Critical patent/JP7750858B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2022561644A 2020-04-07 2021-04-06 生産のためのアデノウイルス発現ベクター及び方法並びに細胞株 Active JP7750858B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025159003A JP2025175172A (ja) 2020-04-07 2025-09-25 生産のためのアデノウイルス発現ベクター及び方法並びに細胞株

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063006266P 2020-04-07 2020-04-07
US63/006,266 2020-04-07
PCT/US2021/025890 WO2021207136A1 (en) 2020-04-07 2021-04-06 Adenoviral expression vector and methods and cell lines for production

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025159003A Division JP2025175172A (ja) 2020-04-07 2025-09-25 生産のためのアデノウイルス発現ベクター及び方法並びに細胞株

Publications (3)

Publication Number Publication Date
JP2023521149A JP2023521149A (ja) 2023-05-23
JP2023521149A5 JP2023521149A5 (https=) 2024-03-29
JP7750858B2 true JP7750858B2 (ja) 2025-10-07

Family

ID=75660398

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022561644A Active JP7750858B2 (ja) 2020-04-07 2021-04-06 生産のためのアデノウイルス発現ベクター及び方法並びに細胞株
JP2025159003A Pending JP2025175172A (ja) 2020-04-07 2025-09-25 生産のためのアデノウイルス発現ベクター及び方法並びに細胞株

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025159003A Pending JP2025175172A (ja) 2020-04-07 2025-09-25 生産のためのアデノウイルス発現ベクター及び方法並びに細胞株

Country Status (9)

Country Link
US (2) US12227754B2 (https=)
EP (1) EP4133090A1 (https=)
JP (2) JP7750858B2 (https=)
KR (1) KR20230008069A (https=)
CN (1) CN115916984A (https=)
AU (1) AU2021251718A1 (https=)
CA (1) CA3174985A1 (https=)
IL (1) IL297178A (https=)
WO (1) WO2021207136A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250091839A (ko) 2023-12-14 2025-06-23 김현우 강판의 부식방지용 페인트 자동 제거장치
WO2025160234A1 (en) * 2024-01-26 2025-07-31 Cystic Fibrosis Foundation Cftr super exon constructs and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060286121A1 (en) 2003-07-25 2006-12-21 Gall Jason G D Adenoviral vector-based vaccines
JP2007515393A (ja) 2003-04-30 2007-06-14 コリクサ コーポレイション Ｗｔ１特異的な免疫治療のための組成物および方法
JP2007527215A (ja) 2003-07-03 2007-09-27 セル ジェネシス インコーポレイテッド アデノウィルスｅ１ａ／ｅ１ｂ補完細胞株
US20180171305A1 (en) 2016-12-20 2018-06-21 Salk Institute For Biological Studies Use of phospholipid scramblase inhibitors for modulating inflammatory immune responses
WO2019060726A1 (en) 2017-09-22 2019-03-28 Genzyme Corporation Variant rnai

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1094974C (zh) * 1998-12-31 2002-11-27 上海华晨生物技术研究所 表达人白细胞介素12的重组腺病毒及其制法和用途
US20040142893A1 (en) * 2002-10-21 2004-07-22 Uichi Ikeda Methods for treating and preventing vascular disease
AU2005243730B2 (en) * 2004-04-12 2010-05-27 Genvec, Inc. Method of using adenoviral vectors to induce an immune response
US7851218B2 (en) 2004-12-13 2010-12-14 Schering Corporation Cell lines for production of replication-defective adenovirus
WO2007134325A2 (en) * 2006-05-15 2007-11-22 Introgen Therapeutics, Inc. Methods and compositions for protein production using adenoviral vectors
CN103966263A (zh) * 2013-02-04 2014-08-06 广州医学院第一附属医院 一种重组人3型腺病毒及其制备方法和应用
US9624510B2 (en) * 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
GB201620968D0 (en) * 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
CN112292449A (zh) * 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007515393A (ja) 2003-04-30 2007-06-14 コリクサ コーポレイション Ｗｔ１特異的な免疫治療のための組成物および方法
JP2007527215A (ja) 2003-07-03 2007-09-27 セル ジェネシス インコーポレイテッド アデノウィルスｅ１ａ／ｅ１ｂ補完細胞株
US20060286121A1 (en) 2003-07-25 2006-12-21 Gall Jason G D Adenoviral vector-based vaccines
US20180171305A1 (en) 2016-12-20 2018-06-21 Salk Institute For Biological Studies Use of phospholipid scramblase inhibitors for modulating inflammatory immune responses
WO2019060726A1 (en) 2017-09-22 2019-03-28 Genzyme Corporation Variant rnai

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Delphine REA et al.，"Recombinant adenovirus-transduced human dendritic cells engineered to secrete interleukin-10 (IL-10) suppress Th1-type responses while selectively activating IL-10－producing CD4+ T cells"，Human Immunology，2004年11月，Vol. 65, No. 11，p.1344-1355，DOI: 10.1016/j.humimm.2004.08.185

Also Published As

Publication number Publication date
US12227754B2 (en) 2025-02-18
KR20230008069A (ko) 2023-01-13
US20210310025A1 (en) 2021-10-07
WO2021207136A1 (en) 2021-10-14
US20250137013A1 (en) 2025-05-01
EP4133090A1 (en) 2023-02-15
IL297178A (en) 2022-12-01
AU2021251718A1 (en) 2022-11-10
JP2023521149A (ja) 2023-05-23
JP2025175172A (ja) 2025-11-28
CN115916984A (zh) 2023-04-04
CA3174985A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
JP2025175172A (ja) 生産のためのアデノウイルス発現ベクター及び方法並びに細胞株
Vorburger et al. Adenoviral gene therapy
EP2675484B1 (en) Improved aav8 vector with enhanced functional activity and methods of use thereof
US7238674B2 (en) Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
Mah et al. Virus-based gene delivery systems
CN101511373B (zh) 用于基因治疗的修饰的因子ⅷ和因子ⅸ基因和载体
US20020192823A1 (en) AAV2 vectors and methods
CA3120289A1 (en) Recombinant viral vectors and nucleic acids for producing the same
CN107864653A (zh) 衣壳
KR20160026841A (ko) 스터퍼/필러 폴리누클레오티드 서열을 포함하는 벡터 및 사용 방법
JP2012016359A (ja) Ｅ１領域内の発現カセットと不活性化されたｅ２ｂポリメラーゼを有するアデノウイルス発現ベクター
JP7654562B2 (ja) 線維芽細胞増殖因子２３関連低リン血症性疾患の遺伝子療法
US20220218844A1 (en) Gene therapy vectors for infantile malignant osteopetrosis
TW202144575A (zh) 使用ａａｖ及治療調配物之苯酮尿症治療
WO2024079531A2 (en) Nucleic acid regulatory elements for gene expression in the liver and methods of use
TW202242124A (zh) 靶向ｔ細胞之ａａｖ載體
Sorroza-Martinez et al. Recent Advances in Therapeutics and Manufacturing Processes of Recombinant Adeno-Associated Virus for the Treatment of Lung Diseases
TWI267552B (en) Replicating adenovirus vectors
JP2025508987A (ja) Ｇｌｐ－１受容体アゴニスト融合物の送達のためのａａｖベクター
JP2024528997A (ja) 放射線誘発性唾液機能低下を予防するためのａｑｐ１遺伝子療法
WO2019228525A1 (en) Lentiviral vector used for treatment of x-scid, lentivirus, and preparation method and application thereof
CN1236057C (zh) 表达人类激肽释放酶的重组腺相关病毒及其制法和用途
WO2026072721A1 (en) Parvovirus compositions and methods for gene therapy
Warrington Jr et al. AAV VECTORS PART I: SEROTYPES, TARGETING AND IMMUNITY

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250225

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250523

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250826

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250925

R150 Certificate of patent or registration of utility model

Ref document number: 7750858

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150